Vivus rises on faster functioning ED drug, not obesity news
This article was originally published in Scrip
Executive Summary
Vivus has not marketed its erectile dysfunction therapy to prescribers nor engaged a partner to help commercialize Stendra (avanafil) in the US, where it was approved more than a year ago, but the company will seek an amendment for the drug's label to differentiate the product from other phosphodiesterase type 5 (PDE5) inhibitors.